KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Debt: 2010-2025

Historic Total Debt for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Sep 2025 value amounting to $5.4 billion.

  • Jazz Pharmaceuticals' Total Debt fell 12.28% to $5.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year decrease of 12.28%. This contributed to the annual value of $6.1 billion for FY2024, which is 6.93% up from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Total Debt is $5.4 billion, which was down 0.05% from $5.4 billion recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Total Debt peaked at $6.7 billion during Q2 2021, and registered a low of $2.1 billion during Q1 2021.
  • Moreover, its 3-year median value for Total Debt was $5.7 billion (2023), whereas its average is $5.7 billion.
  • In the last 5 years, Jazz Pharmaceuticals' Total Debt soared by 220.39% in 2021 and then decreased by 12.28% in 2025.
  • Jazz Pharmaceuticals' Total Debt (Quarterly) stood at $6.0 billion in 2021, then fell by 5.38% to $5.7 billion in 2022, then declined by 0.20% to $5.7 billion in 2023, then climbed by 6.93% to $6.1 billion in 2024, then dropped by 12.28% to $5.4 billion in 2025.
  • Its Total Debt stands at $5.4 billion for Q3 2025, versus $5.4 billion for Q2 2025 and $5.4 billion for Q1 2025.